Department of Pediatric Hematology and Oncology, University Hospital of Policlinico of Bari.
Specialization School in Pediatrics, University of Bari "Aldo Moro".
J Pediatr Hematol Oncol. 2024 Aug 1;46(6):e439-e442. doi: 10.1097/MPH.0000000000002904. Epub 2024 Jun 24.
Hodgkin lymphoma (HL) is among the most commonly occurring malignancies in adolescents. For relapsed/refractory disease, many regimens have been proposed. Novel agents are increasingly used, like brentuximab vedotin (BV), an antiCD30 antibody-drug conjugate, used as a single agent or in combination with classic regimens mainly in adults, while limited is the experience in pediatrics. We report here on 2 boys with aggressive and high-risk relapsed HL, successfully treated with the BV plus dexamethasone, high-dose cytarabine, cisplatin regimen as induction salvage treatment. Our experience provides real-world evidence on the use of BV-dexamethasone, high-dose cytarabine, cisplatin as first-line salvage therapy for relapsed/refractory HL and expands the current therapeutic choices.
霍奇金淋巴瘤（HL）是青少年中最常见的恶性肿瘤之一。对于复发/难治性疾病，已经提出了许多治疗方案。新型药物越来越多地被使用，如 Brentuximab vedotin（BV），一种抗 CD30 抗体-药物偶联物，主要在成人中作为单一药物或与经典方案联合使用，而在儿科中的经验有限。我们在此报告 2 例侵袭性和高危复发 HL 男孩，成功地接受了 BV 联合地塞米松、高剂量阿糖胞苷、顺铂方案作为诱导性挽救治疗。我们的经验为使用 BV-地塞米松、高剂量阿糖胞苷、顺铂作为复发/难治性 HL 的一线挽救治疗提供了真实世界的证据，并扩大了当前的治疗选择。
